Invokana Lawsuit Attorneys
Lawyers for Invokana, Invokamet and other SGLT2 Claims
Hundreds of lawsuits have been filed against Johnson and Johnson’s Janssen Pharmaceuticals subsidiary, AstraZeneca and other SGLT2 manufacturers for severe side effects including pancreatitis, bone fractures, kidney failure, cardio vascular issues, amputations, diabetic ketoacidosis, a serious complication that causes the body to produce excess blood acids (ketones) due to lack of insulin production. If you have been injured due to Invokana, Invokamet or other SGLT2 inhibitor medications, call Simmons and Fletcher, P.C. to be connected with a defective drug and pharmaceutical attorney for a free consultation. 800-298-0111.
What is Invokana, Invokamet and other SGLT2 inhibitors?
Invokana (canagliflozin) is a type 2 diabetes medication that is manufactured by Johnson and Johnson. It falls under the category of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors, and it controls the body’s blood sugar by removing excess sugar through urine. Being the first drug of its class, Invokana was approved by the FDA in 2013, with a similar drug Invokamet (canagliflozin and metformin) being approved the following year. Invokana works by preventing the kidneys from reabsorbing glucose, while most type 2 diabetes medications mainly increase insulin. The drug does so by inhibiting the SGLT2 protein in the kidneys; so instead of reabsorbing sugar, the kidneys secrete it, making the sugar exit the body during urination.
Other SGLT2 inhibitors including Jardiance, Glyxambi , Xiigduo XR and Farxiga
Jardiance (empagliflozin) is an oral SGLT2 inhibitor manufactured and marketed by Boehringer Ingelhein. Following Jardiance’s approval in 2014, Glyxambi, a combination of Jardiance and Tradjenta, another active ingredient used to treat type 2 diabetes, was approved in 2015. Glyxambi is also created and marketed by Boehringer Ingelhein. Farxiga is manufactured by AstraZeneca and Bristol-Myers Squibb, it is a once-daily oral pill used to improve glycemic control in patients with type 2 diabetes. Farxiga, and Xigduo XR, an extended release version of Farxiga, were both approved by the FDA in 2014.
FDA Warnings for Invokana
While minor side effects include urinary tract infections and abdominal pain; more severe side effects include kidney problems, ketoacidosis and even amputations. In fact, in 2017 the FDA added a black box warning to Invokana, saying it causes an increased risk of leg and foot amputations. Other warnings the FDA has increased since Invokana hit the market include diabetic ketoacidosis, kidney injury and cardiovascular problems.
Invokana Multidistrict Litigation (MDL) in New Jersey
Most SGLT2 drug lawsuits are in their early stages or still pending; however, more than 740 cases have been consolidated in the Invokana MDL. Because the FDA added official warnings for these conditions on December 4, 2015, those who suffered severe side effects before this date may still have a claim against the manufacturer.
Invokana, Invokamet and other SGLT2 Attorneys
If you or a loved one has suffered ketoacidosis or other severe side effects after using Invokana, Invokamet or other SGLT2 drugs, contact Simmons and Fletcher, P.C. today. Our attorneys are passionate about helping victims discover the facts of their case so they can make an informed decision about their future. Call us today for a free consultation at 800-298-0111.